JARDIANCE® under the microscope: can it safely protect kidneys Long-Term?

NCT ID NCT06527846

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking over 1,000 Japanese patients with chronic kidney disease who are taking JARDIANCE® (empagliflozin) daily for a long period. Researchers are monitoring side effects and whether the drug helps slow kidney decline in real-world conditions. The goal is to see if the medication remains safe and effective outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (JARDIANCE®)
What this could lead to: If successful, this study could confirm that JARDIANCE® is safe and effective for long-term use in slowing kidney disease progression in a real-world setting.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It only includes Japanese patients, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASE, CHRONIC

Contacts and locations

Locations

Nippon Boehringer Ingelheim Co., Ltd.

Tokyo, 1416017, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.